April 22, 2022
Ultimovacs’ combination immunotherapies in cancer validated by the USPTO
Ultimovacs ASA has received a Notice of Allowance from the United States Patent and Trademarks Office (USPTO) concerning its US patent application 16/306,352 on the use of vaccine-checkpoint inhibitor combinations to treat cancer.